FTRE
Fortrea Holdings Inc.
Healthcare · Biotechnology · NMS
$16.08
Data: 2026-05-28
✓ ETHICAL PASS

Unknown MOAT
HIGH
Data Confidence: 85.7%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$1.3B
Total market value of the company
12.47
Based on estimated future earnings — lower means cheaper
Rev Growth
-2.3%
Year-over-year revenue change
Profit Margin
-16.5%
How much profit the company keeps from each dollar of revenue
-64.5%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$16.00
-0% from current price — median analyst estimate
Recommendation
BUY
Consensus view from 11 analysts covering this stock
About Fortrea Holdings Inc.

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

https://www.fortrea.com

Country: United States Employees: 14,000 Industry: Biotechnology
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.0% N/A
Debt must be below 33% of total assets
Cash Ratio
0.0% N/A
Interest-bearing cash below 33% of assets
Receivables
0.0% N/A
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

MARKUP
Price trending up with increasing momentum
0.115
Positive but modest risk-adjusted returns
-0.0028
No positive edge detected — the data suggests staying out
-0.260
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-22.2%
Historical annualised return based on price data
-85.5%
Largest peak-to-trough decline — the worst it has been
SIDEWAYS
Price consolidating — no clear directional bias
Days in State
16
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

1.91
Significantly more volatile than the market
52W High
$18.67
14% below the year high
52W Low
$3.97
305% above the year low
Avg Volume
1,396,214
Average daily shares traded — higher means easier to buy and sell
6.0
Days it would take all short sellers to cover — higher means more crowded
Short % Float
11.8%
Elevated short interest — bears are positioned against this
N/A
Annual dividend as a percentage of the share price
$-4.81
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

212.70
Heavy leverage — higher financial risk if revenues decline
0.95
Below 1 means short-term obligations exceed liquid assets — risk flag
Quick Ratio
0.83
Like current ratio but excludes inventory — stricter test
Gross Margin
18.9%
Revenue left after cost of goods — higher means pricing power
Operating Margin
0.5%
Profit from core operations before interest and tax
$286M
Positive — the business generates more cash than it spends
Revenue (TTM)
$2.7B
Total revenue over the last 12 months
Net Income
$-446,900,000
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
11
Target High
$20.00
Target Median
$16.00
Target Low
$9.50
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.